Personal Finance

Why Abiomed Soared 14.1% In February

A surgeon in the foreground with an operation happening in background.

What happened

In response to pumping out record quarterly results and sharing a slew of upbeat news announcements with investors, shares of Abiomed (NASDAQ: ABMD) , a medical device maker focused on heart recovery, jumped 14.1% in February according to data from S&P Global Market Intelligence .

So what

Abiomed got off to a fast start in February after it reported strong fiscal third-quarter results:

  • Revenue grew 34% to $154 million.
  • Adjusted net income more than doubled to $32.2 million.
  • Adjusted earnings per share of $0.70 were far higher than the $0.51 that Wall Street had expected.

If that wasn't exciting enough, the company also shared two positive regulatory updates with investors later in the month, including:

  • Winning FDA approval for a label expansion claim for its Impella heart pumps to treat heart failure associated with cardiomyopathy leading to cardiogenic shock.
  • Gaining FDA approval for a label expansion claim for certain Impella heart pumps to be used during elective and urgent high risk percutaneous coronary intervention (PCI) procedures.

Given the upbeat financial results and label expansion wins, it isn't hard to figure out why Abiomed's shares remain on fire.

A surgeon in the foreground with an operation happening in background.

Image source: Getty Images.

Now what

Between label expansion claims, product innovations, and international expansion , there are plenty of reasons for investors to believe that Abiomed's days of hyper growth are here to stay. While the company's stock cannot be called cheap right now -- shares are currently trading for more than 22 times sales and 85 times forward earnings -- I still think the long-term potential of this business is so great that the company can continue to put up market-beating results.

10 stocks we like better than Abiomed

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abiomed wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of March 5, 2018

Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool recommends Abiomed. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ABMD PCI

Other Topics

Stocks

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More